NCT01497704View on ClinicalTrials.gov

Dose-Escalation and Safety Trial of YN968D1

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

May 31, 2015

Conditions
Cancer Patients With Solid Tumors
Interventions
DRUG

YN968D1

Daily dosing of YN968D1 for treatment of solid tumors

Trial Locations (2)

84112

Huntsman Cancer Institute, Salt Lake City

138-736

ASAN Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Bukwang Pharmaceutical, Co., Ltd.

INDUSTRY

lead

Elevar Therapeutics

INDUSTRY

NCT01497704 - Dose-Escalation and Safety Trial of YN968D1 | Biotech Hunter | Biotech Hunter